Section
NCT
Category
Hematological neoplasms
Subcategory
Other indications (e.g. myeloproliferative diseases)
Trial Type
other systemic therapies
Description for experts
Optimization of aftercare following innovative cell therapies
Description for laymen
Optimization of aftercare following innovative cell therapies
JSON Data
{
"short_title": "SPIZ",
"data_mode": "910",
"data_mode_number": "000000047",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "not_applicable",
"ctgov_number": null,
"eudract_number": null,
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Optimierung der Nachsorge nach innovativen Zelltherapien",
"description_laie_en": "Optimization of aftercare following innovative cell therapies",
"description_expert_de": "Optimierung der Nachsorge nach innovativen Zelltherapien",
"description_expert_en": "Optimization of aftercare following innovative cell therapies",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 22
}
